Drug intelligence / Profile preview

SPR3

Development stage: Preclinical
Lead developer: Sporos BioDiscovery
Modality: Small Molecules

Overview

SPR3 is a preclinical-stage small molecule inhibitor of the C-C chemokine receptor type 2 (CCR2), being developed by Sporos BioDiscovery. CCR2 is a critical signaling node that facilitates the recruitment of myeloid-derived suppressor cells (MDSCs) and the conversion of neutrophils into immunosuppressive MDSCs, which can lead to resistance against MAPK pathway inhibitors and immunotherapy. By blocking CCR2, SPR3 aims to prevent these bypass mechanisms, particularly in KRAS-mutant cancers, thereby restoring or enhancing the efficacy of standard-of-care treatments.

Targets

CCR2 (Chemokine (C-C motif) Receptor 2)

Beyond the preview

Go deeper on SPR3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPR3.

Explore the full profile